Literature DB >> 18395916

Expression of connective tissue growth factor in tumor tissues is an independent predictor of poor prognosis in patients with gastric cancer.

Lu-Ying Liu1, Yan-Chun Han, Shu-Hua Wu, Zeng-Hua Lv.   

Abstract

AIM: To examine the expression of connective tissue growth factor (CTGF), also known as CCN2, in gastric carcinoma (GC), and the correlation between the expression of CTGF, clinicopathologic features and clinical outcomes of patients with GC.
METHODS: One hundred and twenty-two GC patients were included in the present study. All patients were followed up for at least 5 years. Proteins of CTGF were detected using the Powervision two-step immunostaining method.
RESULTS: Of the specimens from 122 GC patients analyzed for CTGF expression, 58 (58/122, 47.5%) had a high CTGF expression in cytoplasm of gastric carcinoma cells and 64 (64/122, 52.5%) had a low CTGF expression. Patients with a high CTGF expression showed a higher incidence of lymph node metastasis than those with a low CTGF expression (P = 0.032). Patients with a high CTGF expression had significantly lower 5-year survival rate than those with a low CTGF expression (27.6% vs 46.9%, P = 0.0178), especially those staging I + II + III (35.7% vs 65.2%, P = 0.0027).
CONCLUSION: GC patients with an elevated CTGF expression have more lymph node metastases and a shorter survival time. CTGF seems to be an independent prognostic factor for the successful differentiation of high-risk GC patients staging I + II + III. Over-expression of CTGF in human GC cells results in an increased aggressive ability.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18395916      PMCID: PMC2701536          DOI: 10.3748/wjg.14.2110

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  30 in total

Review 1.  NOV (nephroblastoma overexpressed) and the CCN family of genes: structural and functional issues.

Authors:  B Perbal
Journal:  Mol Pathol       Date:  2001-04

2.  Elevated levels of connective tissue growth factor, WISP-1, and CYR61 in primary breast cancers associated with more advanced features.

Authors:  D Xie; K Nakachi; H Wang; R Elashoff; H P Koeffler
Journal:  Cancer Res       Date:  2001-12-15       Impact factor: 12.701

Review 3.  The modular architecture of a new family of growth regulators related to connective tissue growth factor.

Authors:  P Bork
Journal:  FEBS Lett       Date:  1993-07-26       Impact factor: 4.124

4.  Connective tissue growth factor induces the proliferation, migration, and tube formation of vascular endothelial cells in vitro, and angiogenesis in vivo.

Authors:  T Shimo; T Nakanishi; T Nishida; M Asano; M Kanyama; T Kuboki; T Tamatani; K Tezuka; M Takemura; T Matsumura; M Takigawa
Journal:  J Biochem       Date:  1999-07       Impact factor: 3.387

5.  Global cancer statistics, 2002.

Authors:  D Max Parkin; Freddie Bray; J Ferlay; Paola Pisani
Journal:  CA Cancer J Clin       Date:  2005 Mar-Apr       Impact factor: 508.702

Review 6.  Updates on esophageal and gastric cancers.

Authors:  Amy Gallo; Charles Cha
Journal:  World J Gastroenterol       Date:  2006-05-28       Impact factor: 5.742

7.  Connective tissue growth factor-specific monoclonal antibody therapy inhibits pancreatic tumor growth and metastasis.

Authors:  Nadja Dornhöfer; Suzanne Spong; Kevin Bennewith; Ali Salim; Stephen Klaus; Neeraja Kambham; Carol Wong; Fiona Kaper; Patrick Sutphin; Randall Nacamuli; Rendall Nacalumi; Michael Höckel; Quynh Le; Michael Longaker; George Yang; Albert Koong; Amato Giaccia
Journal:  Cancer Res       Date:  2006-06-01       Impact factor: 12.701

8.  Connective tissue growth factor and its role in lung adenocarcinoma invasion and metastasis.

Authors:  Cheng-Chi Chang; Jin-Yuan Shih; Yung-Ming Jeng; Jen-Liang Su; Been-Zen Lin; Szu-Ta Chen; Yat-Pang Chau; Pan-Chyr Yang; Min-Liang Kuo
Journal:  J Natl Cancer Inst       Date:  2004-03-03       Impact factor: 13.506

9.  Inhibition of connective tissue growth factor (CTGF/CCN2) expression decreases the survival and myogenic differentiation of human rhabdomyosarcoma cells.

Authors:  Stefania Croci; Lorena Landuzzi; Annalisa Astolfi; Giordano Nicoletti; Angelo Rosolen; Francesca Sartori; Matilde Y Follo; Noelynn Oliver; Carla De Giovanni; Patrizia Nanni; Pier-Luigi Lollini
Journal:  Cancer Res       Date:  2004-03-01       Impact factor: 12.701

10.  Connective tissue growth factor: a cysteine-rich mitogen secreted by human vascular endothelial cells is related to the SRC-induced immediate early gene product CEF-10.

Authors:  D M Bradham; A Igarashi; R L Potter; G R Grotendorst
Journal:  J Cell Biol       Date:  1991-09       Impact factor: 10.539

View more
  27 in total

1.  Forkhead transcription factor foxq1 promotes epithelial-mesenchymal transition and breast cancer metastasis.

Authors:  Haijun Zhang; Fanyan Meng; Gang Liu; Bin Zhang; Jun Zhu; Feng Wu; Stephen P Ethier; Fred Miller; Guojun Wu
Journal:  Cancer Res       Date:  2011-02-01       Impact factor: 12.701

2.  CTGF is a therapeutic target for metastatic melanoma.

Authors:  E C Finger; C-F Cheng; T R Williams; E B Rankin; B Bedogni; L Tachiki; S Spong; A J Giaccia; M B Powell
Journal:  Oncogene       Date:  2013-02-25       Impact factor: 9.867

3.  CTGF is overexpressed in papillary thyroid carcinoma and promotes the growth of papillary thyroid cancer cells.

Authors:  Lei Cui; Qing Zhang; Zhengfa Mao; Jixiang Chen; Xuqing Wang; Jianguo Qu; Jianxin Zhang; Dayong Jin
Journal:  Tumour Biol       Date:  2011-04-20

4.  EphB4 is overexpressed in papillary thyroid carcinoma and promotes the migration of papillary thyroid cancer cells.

Authors:  Wang Xuqing; Cui Lei; Mao Zhengfa; Dang Shengchun; Fan Xin; Qu Jianguo; Zhang Jianxin
Journal:  Tumour Biol       Date:  2012-04-24

Review 5.  Cyr61/CTGF/Nov family proteins in gastric carcinogenesis.

Authors:  Tsu-Yao Cheng; Ming-Shiang Wu; Kuo-Tai Hua; Min-Liang Kuo; Ming-Tsan Lin
Journal:  World J Gastroenterol       Date:  2014-02-21       Impact factor: 5.742

6.  Inhibition of connective tissue growth factor (CTGF/CCN2) in gallbladder cancer cells leads to decreased growth in vitro.

Authors:  Patricia Garcia; Pamela Leal; Carmen Ili; Priscilla Brebi; Hector Alvarez; Juan C Roa
Journal:  Int J Exp Pathol       Date:  2013-04-18       Impact factor: 1.925

7.  Increased levels of SLP-2 correlate with poor prognosis in gastric cancer.

Authors:  Dongning Liu; Lei Zhang; Zhiyong Shen; Fei Tan; Yanfeng Hu; Jiang Yu; Guoxin Li
Journal:  Gastric Cancer       Date:  2013-01-31       Impact factor: 7.370

8.  The RNA-binding protein Musashi1 affects medulloblastoma growth via a network of cancer-related genes and is an indicator of poor prognosis.

Authors:  Dat T Vo; Dharmalingam Subramaniam; Marc Remke; Tarea L Burton; Philip J Uren; Jonathan A Gelfond; Raquel de Sousa Abreu; Suzanne C Burns; Mei Qiao; Uthra Suresh; Andrey Korshunov; Adrian M Dubuc; Paul A Northcott; Andrew D Smith; Stefan M Pfister; Michael D Taylor; Sarath C Janga; Shrikant Anant; Christine Vogel; Luiz O F Penalva
Journal:  Am J Pathol       Date:  2012-09-14       Impact factor: 4.307

9.  Clinicopathological significance of SLP-2 overexpression in human gallbladder cancer.

Authors:  Wei-Xin Wang; Qing-Feng Lin; Dong Shen; Shao-Ping Liu; Wei-Dong Mao; Gui Ma; Wei-Dong Qi
Journal:  Tumour Biol       Date:  2013-08-07

10.  Estrogenic GPR30 signalling induces proliferation and migration of breast cancer cells through CTGF.

Authors:  Deo Prakash Pandey; Rosamaria Lappano; Lidia Albanito; Antonio Madeo; Marcello Maggiolini; Didier Picard
Journal:  EMBO J       Date:  2009-01-15       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.